Top line results from the Swedish ongoing Phase II study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented

Hansa Medical AB (publ) today announced that preliminary results of the Sweden based ongoing Phase II study of IdeS were presented today by Professor Gunnar Tufveson at the 26th International Congress of the Transplantation Society in Hong Kong on August 23, 2016. The results show that IdeS has enabled kidney transplantation in all 10 out of 10 included sensitized patients. The Phase II study also shows that IdeS treatment resulted in negative cross match test in all patients, none of the transplanted patients experienced delayed graft function and all 10 transplantations resulted in very good creatinine levels. The ongoing and fully recruited Phase II study at Uppsala University Hospital and Karolinska University Hospital in Huddinge, Sweden, includes 10 patients who received a single dose of IdeS (0.25 or 0.5 mg/kg) before kidney transplantation. The study’s primary focus is to evaluate safety and tolerability of Hansa Medical’s candidate drug IdeS in sensitized kidney transplantation patients. The study is also aimed at identifying an IdeS dose that results in anti-HLA antibody levels acceptable for transplantation within 24 hours from dosing.  Patients in the study are followed for six months after transplantation to continue to evaluate drug safety and kidney function.  The study is expected to be finalized in Q4 2016. Professor Tufveson concludes in his presentation that IdeS treatment is a suitable way to achieve rapid and effective desensitization allowing transplantation in immunized patients and that a dose level of 0.25 mg/kg body weight is a suitable dose. Two additional clinical studies with IdeS in sensitized patients are ongoing: an investigator initiated Phase II study at Cedars-Sinai Medical Center in Los Angeles and a pivotal multicenter study in the US with IdeS in refractory highly sensitized patients. Results from the multicenter study hold the potential to form the basis for filing a Biologics License Application, which is an application to the US Food and Drug Administration (FDA) for authorization to commercialize IdeS in the US. In addition, Hansa Medical is evaluating the possibility of adding various European sites to this multicenter study to better support the regulatory process at the European Medicines Agency, EMA, to gain marketing authorization of IdeS in the European market. The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated below on  August 23, 2016 at 08.30 CET. For further information, please contact: Hansa Medical AB Göran Arvidson, CEO Mobile: 46 70-633 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About IdeS IdeS, a unique molecule with a novel mechanism, is an enzyme that specifically cleaves human IgG antibodies. During 2013, a Phase I clinical trial including 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014, a Phase II study in 8 sensitized patients awaiting kidney transplantation was conducted. Data from the study show that IdeS is effective in reducing anti-HLA antibody levels in highly sensitized patients to levels acceptable for transplantation. The efficacy and safety of IdeS in transplantation are currently investigated in three on-going clinical trials in sensitized kidney patients in Sweden and in the US. In addition to transplantation, IdeS has potential applications in a variety of rare autoimmune diseases. IdeS is protected by several patents and results of studies with IdeS have been published in a number of peer reviewed scientific journals. About Hansa Medical AB Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading